Nkarta, Inc. Research and Development Expense
Nkarta, Inc. (NKTX) reported Research and Development Expense of $29.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Nkarta, Inc. research and development expense for the quarter ending 2026-06-30 was $29.05M, a 39.79% increase year-over-year.
- Nkarta, Inc. research and development expense for the quarter ending 2026-03-31 was $24.99M, a 3.38% increase year-over-year.
- Nkarta, Inc. research and development expense for the quarter ending 2025-12-31 was $25.28M, a 9.31% increase year-over-year.
- Nkarta, Inc. research and development expense for the quarter ending 2025-09-30 was $20.20M, a 20.01% decline year-over-year.
- Nkarta, Inc. research and development expense for fiscal 2025 was $90.43M, a 6.53% decline from fiscal 2024.
- Nkarta, Inc. research and development expense for fiscal 2024 was $96.74M, a 0.03% decline from fiscal 2023.
- Nkarta, Inc. research and development expense for fiscal 2023 was $96.77M, a 6.46% increase from fiscal 2022.
- Nkarta, Inc. research and development expense for fiscal 2022 was $90.90M, a 43.34% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $29.05M 10-Q · filed 2026-08-10 | $54.03M 10-Q · filed 2026-08-10 | $79.31M derived: sum of 3 quarters · filed 2026-08-10 | $99.51M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $24.99M 10-Q · filed 2026-05-12 | $50.27M derived: sum of 2 quarters · filed 2026-05-12 | $70.47M derived: sum of 3 quarters · filed 2026-05-12 | $91.25M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | $25.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $45.48M derived: sum of 2 quarters · filed 2026-03-25 | $66.26M derived: sum of 3 quarters · filed 2026-08-10 | $90.43M 10-K · filed 2026-03-25 | ||
| 2025-09-30 | $20.20M 10-Q · filed 2025-11-10 | $40.98M derived: sum of 2 quarters · filed 2026-08-10 | $65.15M 10-Q · filed 2025-11-10 | $88.28M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $20.78M 10-Q · filed 2026-08-10 | $44.95M 10-Q · filed 2026-08-10 | $68.08M derived: sum of 3 quarters · filed 2026-08-10 | $93.33M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $24.17M 10-Q · filed 2026-05-12 | $47.30M derived: sum of 2 quarters · filed 2026-05-12 | $72.55M derived: sum of 3 quarters · filed 2026-05-12 | $95.68M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $23.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $48.38M derived: sum of 2 quarters · filed 2026-03-25 | $71.51M derived: sum of 3 quarters · filed 2026-03-25 | $96.74M 10-K · filed 2026-03-25 | ||
| 2024-09-30 | $25.25M 10-Q · filed 2025-11-10 | $48.38M derived: sum of 2 quarters · filed 2025-11-10 | $73.62M 10-Q · filed 2025-11-10 | $96.94M derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $23.13M 10-Q · filed 2025-08-12 | $48.37M 10-Q · filed 2025-08-12 | $71.69M derived: sum of 3 quarters · filed 2025-08-12 | $93.88M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $25.24M 10-Q · filed 2025-05-14 | $48.56M derived: sum of 2 quarters · filed 2025-05-14 | $70.75M derived: sum of 3 quarters · filed 2025-05-14 | $95.88M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $23.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $45.52M derived: sum of 2 quarters · filed 2025-03-26 | $70.64M derived: sum of 3 quarters · filed 2025-03-26 | $96.77M 10-K · filed 2025-03-26 | ||
| 2023-09-30 | $22.19M 10-Q · filed 2024-11-07 | $47.32M derived: sum of 2 quarters · filed 2024-11-07 | $73.45M 10-Q · filed 2024-11-07 | $100.30M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $25.12M 10-Q · filed 2024-08-13 | $51.26M 10-Q · filed 2024-08-13 | $78.10M derived: sum of 3 quarters · filed 2024-08-13 | $101.54M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $26.14M 10-Q · filed 2024-05-09 | $52.98M derived: sum of 2 quarters · filed 2024-05-09 | $76.41M derived: sum of 3 quarters · filed 2024-05-09 | $97.46M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $26.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $50.28M derived: sum of 2 quarters · filed 2024-03-21 | $71.33M derived: sum of 3 quarters · filed 2024-03-21 | $90.90M 10-K · filed 2024-03-21 | ||
| 2022-09-30 | $23.43M 10-Q · filed 2023-11-09 | $44.48M derived: sum of 2 quarters · filed 2023-11-09 | $64.05M 10-Q · filed 2023-11-09 | $81.35M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $21.05M 10-Q · filed 2023-08-10 | $40.62M 10-Q · filed 2023-08-10 | $57.92M derived: sum of 3 quarters · filed 2023-08-10 | $74.53M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $19.57M 10-Q · filed 2023-05-11 | $36.87M derived: sum of 2 quarters · filed 2023-05-11 | $53.48M derived: sum of 3 quarters · filed 2023-05-11 | $69.44M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $17.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $33.92M derived: sum of 2 quarters · filed 2023-03-16 | $49.87M derived: sum of 3 quarters · filed 2023-03-16 | $63.41M 10-K · filed 2023-03-16 | ||
| 2021-09-30 | $16.62M 10-Q · filed 2022-11-09 | $32.57M derived: sum of 2 quarters · filed 2022-11-09 | $46.11M 10-Q · filed 2022-11-09 | $57.38M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $15.96M 10-Q · filed 2022-08-11 | $29.50M 10-Q · filed 2022-08-11 | $40.77M derived: sum of 3 quarters · filed 2022-08-11 | $50.59M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $13.54M 10-Q · filed 2022-05-12 | $24.81M derived: sum of 2 quarters · filed 2022-05-12 | $34.64M derived: sum of 3 quarters · filed 2022-05-12 | $42.50M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $11.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $21.10M derived: sum of 2 quarters · filed 2022-03-17 | $28.96M derived: sum of 3 quarters · filed 2022-03-17 | $36.22M 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $9.83M 10-Q · filed 2021-11-10 | $17.69M derived: sum of 2 quarters · filed 2021-11-10 | $24.95M 10-Q · filed 2021-11-10 | $31.63M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $7.86M 10-Q · filed 2021-08-12 | $7.86M 10-Q · filed 2020-08-20 | $15.12M 10-Q · filed 2021-08-12 | $15.12M 10-Q · filed 2020-08-20 | $21.80M derived: sum of 3 quarters · filed 2021-08-12 | $26.42M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $7.26M 10-Q · filed 2021-05-13 | $13.94M derived: sum of 2 quarters · filed 2021-05-13 | $18.56M derived: sum of 3 quarters · filed 2021-05-13 | $22.18M derived: sum of 4 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $6.68M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $11.30M derived: sum of 2 quarters · filed 2021-03-25 | $14.92M derived: sum of 3 quarters · filed 2021-03-25 | $17.22M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $4.62M 10-Q · filed 2020-11-12 | $8.24M derived: sum of 2 quarters · filed 2020-11-12 | $10.54M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $3.62M 10-Q · filed 2020-08-20 | $5.91M 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |